Glioblastoma Multiforme (GBM) - Competitive Landscape
Summary
This reports provides a data-driven overview of the current and future competitive landscape in GBM therapeutics.
- More than 79,000 incident cases of GBM are anticipated in 2023 in the 16 countries covered in GlobalData’s epidemiology forecast for GBM.
- Only a handful of innovator treatment options approved for GBM, the current major player in the GBM market is Roche.
- Out of 803 molecules in the pipeline for GBM, 19 drugs are in Phase III and 171 drugs are in Phase II.
- The clinical trial space in GBM is a mix of commercial as well as academic sponsors, with the US emerging as the key country for conducting Phase III trials.
- In deals involving companies developing GBM assets, partnerships were the most prominent deals type ventured globally.
GlobalData’s GBM: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include -
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the GBM market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global GBM market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
- Key Findings
- Disease Overview
- Disease Etiology Symptoms
- Epidemiology Overview
- Epidemiology Overview – Incident Cases of GBM in 2023 and 2028
- Treatment Overview
- Treatment Guidelines
- Marketed Drugs Assessment
- Marketed Drugs – Leading Marketed Drugs in GBM
- Marketed Drugs – Overview by Mechanism of Action
- Marketed Drugs – Overview by Route of Administration
- Marketed Drugs – Overview by Molecule Type
- Marketed Drug Profile – Roche's Avastin
- Pricing and Reimbursement Assessment
- Marketed Drugs – Annual Cost of Therapy
- Marketed Drugs – Time to Pricing for Avastin
- Pipeline Drugs Assessment
- Pipeline Drugs Overview – Late-Stage Pipeline Drugs in GBM
- Pipeline Drugs – Overview by Development Stage
- Pipeline Drugs – Overview by Mechanism of Action
- Pipeline Drugs – Overview by Route of Administration
- Pipeline Drugs – Overview by Molecule Type
- Pipeline Drugs – Phase Transition Success Rate and Likelihood of Approval in GBM
- Pipeline Drugs – Phase Transition Success Rate and Likelihood of Approval in Oncology and GBM
- Clinical Trials Assessment
- Clinical Trials in GBM – Historical Overview
- Clinical Trials in GBM – Overview by Phase
- Clinical Trials in GBM – Overview by Status
- Clinical Trials in GBM – Overview by Phase for Ongoing and Planned Trials
- Clinical Trials in GBM – Trials with a Virtual Component
- Clinical Trials in GBM – Geographic Overview
- Clinical Trials in GBM – Single-Country and Multinational Trials by Region
- Clinical Trials in GBM – Top Sponsors with Breakdown by Phase
- Clinical Trials in GBM – Top Sponsors with Breakdown by Status
- Clinical Trials in GBM – Overview by Endpoint Status
- Clinical Trials in GBM – Overview by Race and Ethnicity
- Clinical Trials in GBM – Enrollment Data
- Clinical Trials in GBM – Overview of Sites by Geography
- Clinical Trials in GBM – Top 20 Countries for Trial Sites
- Clinical Trials in GBM – Top 20 Sites Globally
- Clinical Trials – Feasibility Analysis: Geography Overview
- Clinical Trials – Feasibility Analysis: Benchmark Models for GBM
- Deals Landscape
- Deals Landscape – Mergers, Acquisitions, and Strategic Alliances in GBM by Region
- Deals Landscape – Recent Mergers, Acquisitions, and Strategic Alliances in GBM
- Commercial Assessment
- Commercial Assessment – Key Market Players in GBM
- Future Market Catalysts
- Future Market Catalysts – Upcoming Market Catalysts in GBM
- Appendix
- Methodology
- Methodology – Sales Forecasts
- Methodology – Pricing and Reimbursement
- Methodology – Phase Transition Success Rate and Likelihood of Approval Analysis
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook